Rallybio (RLYB) News Today $0.26 -0.01 (-3.07%) Closing price 04:00 PM EasternExtended Trading$0.27 +0.01 (+2.71%) As of 07:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Jones Trading Downgrades Rallybio (RLYB)April 15 at 5:04 PM | msn.comAnalysts Set Rallybio Co. (NASDAQ:RLYB) PT at $9.75April 15 at 3:07 AM | americanbankingnews.comRallybio downgraded to Hold from Buy at JonesResearchApril 14 at 11:56 PM | markets.businessinsider.comHC Wainwright Reiterates Neutral Rating for Rallybio (NASDAQ:RLYB)April 12 at 2:24 AM | americanbankingnews.comResearch Analysts Set Expectations for Rallybio Q2 EarningsApril 12 at 1:39 AM | americanbankingnews.comRallybio downgraded to In Line from Outperform at Evercore ISIApril 12 at 12:26 AM | markets.businessinsider.comRallybio (RLYB) was downgraded to a Hold Rating at H.C. WainwrightApril 10, 2025 | markets.businessinsider.comRallybio Stock Short Interest Report | NASDAQ:RLYB | BenzingaApril 9, 2025 | benzinga.comRallybio discontinues RLYB212 programApril 9, 2025 | markets.businessinsider.comHC Wainwright & Co. Downgrades Rallybio (RLYB)April 9, 2025 | msn.comCitizens JMP downgrades Rallybio on RLYB212 discontinuationApril 9, 2025 | markets.businessinsider.comJMP Securities downgrades Rallybio (RLYB) to a HoldApril 9, 2025 | theglobeandmail.comRallybio Stock Plunges After Program For Pediatric Bleeding Disorder DisappointsApril 8, 2025 | benzinga.comRallybio Discontinues Development of Treatment for Prevention of Rare Immune DisorderApril 8, 2025 | marketwatch.comRallybio to Discontinue Development of RLYB212 for Prevention of FNAITApril 8, 2025 | finance.yahoo.comRallybio reports Q4 EPS (25c), consensus (30c)March 13, 2025 | markets.businessinsider.comRallybio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business UpdatesMarch 13, 2025 | finance.yahoo.comRallybio to Present at the TD Cowen 45th Annual Health Care ConferenceFebruary 25, 2025 | finance.yahoo.comRallybio to Present at the TD Cowen 45th Annual Health Care ConferenceFebruary 25, 2025 | businesswire.comRallybio stock plunges to 52-week low of $0.73 amid market challengesFebruary 13, 2025 | msn.comJMP Securities Sticks to Their Buy Rating for Rallybio (RLYB)February 11, 2025 | markets.businessinsider.comRallybio Announces Initiation of Dosing in RLYB212 Phase 2 Clinical TrialFebruary 11, 2025 | finance.yahoo.comRallybio begins Phase 2 trial for FNAIT prevention therapyFebruary 11, 2025 | msn.comRallybio announces initiation of dosing in RLYB212 Phase 2 trialFebruary 11, 2025 | markets.businessinsider.comRallybio’s Promising Pipeline and Clinical Milestones Earns Buy Rating from Analyst Jonathan WollebenJanuary 11, 2025 | markets.businessinsider.comRallybio Highlights 2024 Accomplishments and Anticipated Milestones for 2025January 10, 2025 | tmcnet.comPromising Preclinical Data and Clinical Advancements Justify Buy Rating for RallybioDecember 11, 2024 | markets.businessinsider.comRallybio Announces Promising RLYB212 and RLYB332 Preclinical Data at the 66th American Society of Hematology Annual MeetingDecember 10, 2024 | businesswire.comRallybio price target lowered to $7 from $8 at JMP SecuritiesDecember 6, 2024 | markets.businessinsider.comRallybio’s RLYB116 Program Developments and Financial Stability Support Buy RatingDecember 5, 2024 | markets.businessinsider.comTD Cowen Keeps Their Buy Rating on Rallybio (RLYB)December 5, 2024 | markets.businessinsider.comRallybio’s RLYB116: Promising Developments and Buy Rating Driven by Enhanced Manufacturing and Potential in Phase 1 TrialsDecember 4, 2024 | markets.businessinsider.comRallybio to Initiate RLYB116 Confirmatory Clinical PK/PD Study in Second Quarter 2025December 2, 2024 | finance.yahoo.comRallybio Flat on Release of New FindingsNovember 27, 2024 | baystreet.caRallybio Announces Publication of Target-Mediated Drug Disposition Modeling and Simulations Informing the RLYB212 Dosing Regimen in Pregnant WomenNovember 27, 2024 | businesswire.comRallybio to Present at the 2024 Evercore ISI HealthCONx ConferenceNovember 26, 2024 | finance.yahoo.comRallybio to Provide Update on RLYB116 Program, an Innovative Subcutaneously Injected C5 InhibitorNovember 25, 2024 | finance.yahoo.comRallybio’s Promising Advances and Financial Projections Earn ‘Buy’ Rating from AnalystNovember 22, 2024 | markets.businessinsider.comRallybio announces initiation of Phase 2 clinical trial of RLYB212November 22, 2024 | markets.businessinsider.comRallybio Reports Third Quarter 2024 Financial Results and Provides Business UpdatesNovember 8, 2024 | finance.yahoo.comRallybio’s Strategic Clinical Advancements and Financial Stability Justify Buy RatingNovember 8, 2024 | markets.businessinsider.comTwo former Alexion leaders fight through layoffs and a tough market to maintain a rare disease biotechNovember 6, 2024 | finance.yahoo.comRallybio’s trial applications of RLYB212 in pregnant women with FNAIT approvedOctober 30, 2024 | markets.businessinsider.comRallybio (NASDAQ:RLYB) Stock Quotes, Forecast and News SummaryOctober 10, 2024 | benzinga.comRallybio shares hold Buy rating on HPP treatment dataOctober 3, 2024 | investing.comBuy Rating on Rallybio Amidst Promising Developments in HPP Treatment and Potential Market DisruptionOctober 2, 2024 | markets.businessinsider.comRallybio to Present Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations at the American Society of Human Genetics 2024 Annual MeetingSeptember 23, 2024 | businesswire.comFierce Names Rallybio to the 2024 Fierce 50 List as an Innovation HonoreeSeptember 9, 2024 | finance.yahoo.comBuy Rating on Rallybio Stock Fueled by Promising RLYB212 Trial Outcomes and Potential FNAIT Treatment BreakthroughSeptember 4, 2024 | markets.businessinsider.comBuy Rating on Rallybio: Promising RLYB212 Developments Signal Strong Market PotentialAugust 30, 2024 | markets.businessinsider.com Remove Ads Get Rallybio News Delivered to You Automatically Sign up to receive the latest news and ratings for RLYB and its competitors with MarketBeat's FREE daily newsletter. Email Address RLYB Media Mentions By Week RLYB Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RLYB News Sentiment▼0.140.80▲Average Medical News Sentiment RLYB News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RLYB Articles This Week▼201▲RLYB Articles Average Week Remove Ads Get Rallybio News Delivered to You Automatically Sign up to receive the latest news and ratings for RLYB and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Caribou Biosciences News Cardiol Therapeutics News HilleVax News MacroGenics News Renovaro News Adlai Nortye News Vor Biopharma News Vistagen Therapeutics News InflaRx News IGM Biosciences News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RLYB) was last updated on 4/15/2025 by MarketBeat.com Staff From Our Partners[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rallybio Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rallybio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
